Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 1/20 | 0.46 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1241912 | 0.89 | NR1I2 (0.50) | NR1I2MAT2AMAPK14ALDH1A1GLA | |
| SCHEMBL1243685 | 0.84 | NR1I2 (0.62) | NR1I2MAT2AELANEPBRM1 | |
| SCHEMBL12445706 | 0.84 | NR1I2 (0.62) | NR1I2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL1244175 | 0.83 | NR1I2 (0.45) | NR1I2MAT2AMAPK14ALDH1A1GLA | |
| SCHEMBL1244284 | 0.81 | NR1I2 (0.44) | NR1I2MAPK14ALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL1244384 | 0.77 | NR1I2 (0.53) | NR1I2MAPK14 | |
| SCHEMBL1244256 | 0.75 | NR1I2 (0.40) | NR1I2PBRM1 | |
| SCHEMBL1244608 | 0.74 | MAT2A (0.36) | NR1I2MAT2AMAPK14ALDH1A1GLA | |
| SCHEMBL1244263 | 0.73 | MAPK14 (0.43) | NR1I2MAT2AMAPK14ALDH1A1HPGD | |
| Trifluoroacetic Acid SCHEMBL1244604 | 0.69 | NR1I2 (0.67) | NR1I2MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| EP-1915373-B1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2013-05-22 | — | — | EP | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | CHEN MENG-HSIN | 2011-07-28 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879875-B2 | such as 6-(2,4-difluorophenyl)-1-[2-fluoro-5-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]-2H-quinolizin-2-one, used as antipyretics, analgesics, or in the treatment of arthritis, osteoarthritis, eczema, psoriasis and vision defects | Merk Sharp & Dohme Corp. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MERCK SHARP & DOHME LLC | 2009-05-21 | — | — | US | disclosed |
| EP-1915373-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | Merck and Co., Inc. (US) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2007021710-A1 | HETEROBICYCLIC COMPOUNDS USEFUL AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131472-A1 | P38 Kinase Inhibiting Agents | MAPK1, MAPK8, MAPK7 | NR1I2 417/4885FLT1 467/4885CDK8 263/4885 |
| US-20110183959-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPK7 | NR1I2 589/4885FLT1 489/4885CDK8 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.